PIONEERING PRECISION IN
|
|
|
|
At Photonic Pharma LLC, we focus on the early phase of drug development - Lead Discovery - using a game-changing technology platform that combines breakthroughs in fluorescent biosensor engineering and fluorescence lifetime detection in living cells. Thus we achieve a dramatic 30-fold increase in the precision of high-throughput screening of small-molecule libraries, with the potential to transform the productivity of pharmaceutical development.
We partner with industrial and academic collaborators, applying our proprietary advancements in structure-based drug-screening technology, to discover novel small-molecule effectors of therapeutically important protein targets. We have assembled a robust and highly integrated network of techniques, concepts, facilities and collaborators to address a wide range of therapeutic goals. |
PHOTONIC PHARMA NEWS:
Photonic Pharma is pleased to report the publication of two manuscripts co-authored with our collaborators:
Photonic Pharma is pleased to report the publication of two manuscripts co-authored with our collaborators:
- Joint publication with Bristol Myers Squibb (BMS) in SLAS Discovery entitled, “HTS driven by fluorescence lifetime detection of FRET identifies activators and inhibitors of cardiac myosin.”
- Joint publication with the University of Minnesota (UMN) in ASN Neuro entitled, “Advancements in a FRET biosensor for live-cell fluorescence-lifetime high-throughput screening of alpha-synuclein.”
For full story and other news, please visit our News page.